Top Markets
#1 OSK OSK +15.39%
#2 MarsCoin MarsCoin +12.21%
#3 Tornado Cash Tornado Cash +6.73%
#4 HOME HOME +6.37%
#5 UnifAI Network UnifAI Network +4.86%
#6 AI XOVIA AI XOVIA +4.25%
#7 Pyth Network Pyth Network +3.64%
#8 Backpack Backpack +3.30%
#9 Story Story +3.06%
#10 Rain Rain +2.82%
Coin of the day
OSK OSK
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Kedudukan dalam Saham #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Harga Saham
$4.64
Disegerakkan terakhir: 2022-09-12
Modal Pasaran
$293.43M
Perubahan (1 hari)
0.87%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Adagio Therapeutics, Inc. (ADGI)

Kategori

Healthcare
Pendapatan untuk Adagio Therapeutics, Inc. (ADGI)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Adagio Therapeutics, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Adagio Therapeutics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH